Drug Trial Radar · NCT05531682
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Jun 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Oct 25, 2022
Primary completion
May 23, 2023
Study completion Jan 4, 2024
Sponsor
- Lead sponsor
- Huabo Biopharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the efficacy and safety of HB0017 in subjects with moderate to severe plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
PlaceboOther
Subjects will receive several injections of Placebo
HB0017Drug
Subjects will receive HB0017 in different dosing regimens
Primary outcomes
What the sponsor says the trial is designed to measure.
- PASI 90 responseTime frame: Week 12
- sPGA 0/1 responseTime frame: Week 12
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Shanghai Skin Disease Hospital
Shanghai, China
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
The first hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Dermatology Hospital of Jiangxi Province
Nanchang, Jiangxi, China
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China
Skin Disease Hospital of Shandong First Medical University
Jinan, Shandong, China
Yantai Yuhuangding hospital
Yantai, Shandong, China
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
The Third People's Hospital of Hangzhou
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.